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BACKGROUND: The last decade has seen significant progress in understanding the molecular biology of pancreatic adenocarcinoma.
There is now an urgent need to translate these molecular techniques to clinical practice in order to improve diagnosis and prediction
of response to treatment. The objectives of this study are to utilise poly(A) RT–PCR to measure expression levels of diagnostic
Indicator genes, selected from microarray studies, of RNA from intraoperatively sampled pancreatic ductal juice and to correlate these
expression levels with those in matched pancreatic tissue resection samples.
METHODS: Intraoperative sampling of pancreatic juice and collection of matched tissue samples was undertaken in patients undergoing
pancreaticoduodenectomy for suspected tumour. RNA was isolated and poly(A) PCR and real-time PCR used to measure
expression levels of 30 genes. Spearman’s rank correlation test was used to examine the relationship of gene expression between
pancreatic juice and tissue.
RESULTS: Of the 30 Indicator genes measured, just one, ANXA1, showed a significant correlation of expression level between pancreatic
juice and tissue samples, whereas three genes, IGFBP3 (Pp0.035), PSCA (Pp0.001) and SPINK1 (Pp0.05), showed significantly
different expression between cancerous and benign pancreatic tissue samples.
CONCLUSIONS: These results demonstrate that RNA analysis of pancreatic juice is feasible using the poly(A) cDNA technique, that
correlation of gene expression exists between pancreatic juice and tissue for very few genes and that gene expression profiling can
distinguish between benign and malignant pancreatic tissue. This indicates possible use of the technique for measurement of Indicator
genes in pancreatic tissue for diagnosis of pancreatic cancer from very small tissue samples.
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Carcinoma of the pancreas (PC) is an aggressive disease and the
fourth leading cause of cancer-related mortality in the Western world
(Jemal et al, 2009). The 5-year survival rates for affected patients are
a dismal 3%, emphasising the need for studies to better understand
the molecular biology of pancreatic cancer and to translate this
knowledge to clinical practice (Neoptolemos et al, 2001).
Increased knowledge of the molecular basis of cancer in general
has led to a better understanding of the pathobiology of most
cancers, with the possibility of improved diagnosis and develop-
ment of novel treatments; this is also the case for pancreatic
cancer. Recent advances in global gene expression profiling have
provided molecular markers for cancer diagnosis, and there is a
need to develop methods for their measurement in routine clinical
samples.
Global cDNA amplification, by poly(A) PCR, allows marker
genes to be detected at very low levels, improving sensitivity, while
also providing an improved level of specificity through the ability
to analyse multiple genes (Brady and Iscove, 1993; Sakhinia et al,
2005; Byers et al, 2008). Critically, global cDNA permits analysis of
very small numbers of cells. This is of particular relevance in
enabling measurement of gene expression profiles from cells
isolated from pancreatic juice, providing a relatively noninvasive
method for diagnosis (Oliveira-Cunha et al, 2010a).
Additionally, the poly(A) PCR method can produce an
essentially permanent archive of representative cDNA suitable
for screening with multiple gene-specific probes. Furthermore, the
method is rapid (all samples can be prepared and screened within
48h) and of particular importance for clinical use (Brady et al,
1995; Sakhinia et al, 2005; Byers et al, 2008; Oliveira-Cunha et al,
2010a,b).
This study explores the feasibility of gene expression profiling
from RNA isolated from pancreatic ductal juice and tests the
hypothesis that detection of gene signatures, the so-called
Indicator genes, measured by globally amplified poly(A) cDNA
in ductal juice from patients with pancreatic cancer will provide a
high degree of correlation with Indicator genes detected by the
same method in the tumour samples of the same patients. To
test this hypothesis, RNA was extracted from pancreatic juice
and tissue obtained intraoperatively from patients undergoing
pancreaticoduodenectomy. Poly(A) PCR was used to globally
amplify the RNA followed by measurement of the expression levels
of Indicator genes by real-time PCR. The gene expression profiles
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sfor pancreatic juice were then compared with those for the parallel
pancreatic tissue samples.
MATERIALS AND METHODS
Study population
Pancreatic juice was collected by intraoperative aspiration of the
main pancreatic duct in patients undergoing pancreaticoduode-
nectomy at Manchester Royal Infirmary between May 2007 and
June 2009. For all patients a matched tissue sample from the
main tumour was obtained from the fresh specimen under direct
vision in the histopathology laboratory. The study protocol had
local ethical committee approval and written informed consent
was obtained from all patients. In all, 45 patients were included;
sufficient pancreatic juice was obtained in 41 patients with
matched pancreatic tissue/pancreatic juice in 34 of these patients.
Histological analysis confirmed pancreatic/periampullary malig-
nancy in 37 cases (11 ductal adenocarcinomas, 14 ampullary carci-
nomas, 3 cholangiocarcinomas, 4 intraductal papillary mucinous
neoplasms (IPMNs), 2 neuroendocrine tumour, 2 mucinous
cystic neoplasms (MCNs) and 1 acinar cell carcinoma). Of the
non-cancer group, seven were chronic pancreatitis and one
autoimmune pancreatitis. In the subset of 34 patients with
matched pancreatic tissue and juice, the diagnoses were: 10 ductal
adenocarcinomas, 12 ampullary carcinomas, 2 cholangiocarcino-
mas, 1 neuroendocrine tumour, 3 IPMNs, 1 MCN, 1 autoimmune
pancreatitis and 4 chronic pancreatitis.
Extraction of RNA and global amplification of
polyadenylated mRNAs (poly(A) RT–PCR)
Isogen-LS (Wako, Osaka, Japan) was used in combination with
RNeasy mini Kit (Qiagen, Crawley, UK) for total RNA extraction
and purification from pancreatic juice. Total RNA from pancreatic
tissue was extracted following the RNeasy kit (Qiagen, Hilden,
Germany) according to the manufacturer’s instructions. Samples
were then quantified using a NanoDrop ND-1000 spectrophot-
ometer (NanoDrop Technologies, Wilmington, DE, USA) analysis
and RNA integrity was checked by Agilent 2100 Bioanalyzer
(Agilent Technologies, Waldbronn, Germany) according to the
manufacturer’s instructions. The poly(A) PCR method has three
steps, namely poly(A) primed reverse transcription to produce a
first-strand cDNA for each mRNA; polyadenylation of the first-
strand cDNA, rendering it defined at both ends; and polymerase
chain reaction using a poly(dT) primer, which anneals to the
poly(A) site on the first-strand cDNA. We performed poly(A) PCR
on RNA isolated following standard published protocols.
TaqMan real-time quantitative PCR
TaqMan PCR primers and probes were designed for 30 Indicator
genes that have previously been reported as overexpressed in
pancreatic cancer together with two housekeeping genes (GAPDH
and PSMB6) using Custom TaqMan Gene Expression Assays
(Applied Biosystems, Foster City, CA, USA); details of all primers
and probes used are listed in Supplementary Table 1 online. The
genes studied were selected after literature review of microarray
data. The selected genes include a range of genes covering lineage
markers, cell cycle markers and activation markers in order to
maximise possibility of detection of genes that are overexpressed
in pancreatic cancer, metastatic disease, ductal epithelial cells and
chronic pancreatitis. All PCR primer pairs were designed for an
mRNA sequence within 300 base pair (bp) of the poly(A) signal of
each Indicator gene.
The real-time PCR reactions were performed in 96-well optical
reaction plates, in a final volume of 25ml, containing 12.5mlo f
TaqMan Universal PCR Mastermix (Applied Biosystems), 1.25mlo f
Custom TaqMan Gene Expression Assays Primers and probes
(Applied Biosystems), 8.75ml of UltraPure DEPC water (Invitro-
gen, Carlsbad, CA, USA) and 2.5ml of cDNA. All samples were
analysed using an ABI Prism 7900HT sequence detection system
(Applied Biosystems).
Amplification plots indicating fluorescence intensity at each
cycle were obtained from which Ct values were measured for each
sample. PCRs were run in triplicates for each sample and Ct
averages were obtained. The average Ct value for each gene for
each patient was calculated from the triplicates, followed by
normalisation to the average of the two housekeeping genes
following the 2
DDCt method (Livak and Schmittgen, 2001; Schefe
et al, 2006; Yuan et al, 2008).
Statistical analysis
Statistical analyses were carried out using Excel (Microsoft,
Redmond, WA, USA) and SPSS (Statistical Package for Social
Sciences, Woking, Surrey, UK) version 17. Relative fold changes
were calculated using the DDCt method (Livak and Schmittgen,
2001; Schefe et al, 2006; Yuan et al, 2008).
The data were not normally distributed; therefore, nonpara-
metric tests were used. Spearman’s rank correlation was used to
examine the relationship between pancreatic juice and pancreatic
tissue samples. Statistical analysis of the expression levels of the
30 Indicator genes in the benign and cancer groups was performed
using the Mann–Whitney test, with a P-value of at least 0.05 for
statistical significance. As the expression levels for all the genes fall
across a wide range, the log10 scale was used to plot all values to aid
visual comparison. The ranking of the expression levels of
Indicator genes between samples was presented as the mean rank
statistical difference. False discovery rate analysis was used to
control for multiple comparisons. The q-value is defined to be the
FDR analogue of the P-value and should be o0.05 to be considered
significant.
RESULTS
RNA extraction
Total RNA was successfully extracted from all 41 samples of
pancreatic juice and all 34 samples of pancreatic tissue.
For pancreatic juice the median RNA yield was 68.45ngml
–1
(range from 2.75 to 1418ngml
–1, s.d.±268.3ngml
–1). RNA quality,
assessed by RNA integrity number (RIN), gave a median RIN of 5.5
(range from 1.9 to 10). Analysis of the RIN, purity ratios and gel
electrophoretic results in combination demonstrated good-quality
RNA in 25 cases and poor-quality RNA in 16 cases.
For pancreatic tissue, the median RNA yield was 132ngml
–1
(range from 3.8 to 2594ngml
–1, s.d.±643ngml
–1). The median
purity ratio 260/280 was 2.09 (range from 1.41 to 2.15, s.d.±0.19)
for total RNA of pancreatic tissue.
Poly(A) PCR
Poly(A) cDNA was generated from mRNA extracted from all
samples of pancreatic juice and tissue. The cDNA quantity,
assessed by gel electrophoresis, generated from each sample, was
highly reproducible over at least duplicate tests, demonstrating the
reliability of the method.
Real-time PCRs
After real-time PCR, Ct values were obtained for each sample and
gene. Samples were normalised according to Ct values of the
average for both housekeeping gene in each sample. Figure 1
illustrates the median gene expression levels (median DCt values in
logarithmic scale) of all genes tested.
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sGene expression levels in pancreatic juice compared with
pancreatic tissue samples
Median gene expression levels in pancreatic juice were similar to
that in the corresponding resection specimen, with the exception
of TFF2 and S100P. A statistically significant correlation was
present for ANXA1 (Pp0.043), MSLN (Pp0.037) and PLAT
(Pp0.046). However, these P-values are results of multiple
comparisons; therefore, false discovery rate (FDR) control was
used for correction. The correlation coefficients are shown in
Table 1; none of the 30 genes were significant by FDR at a q-value
of o0.05.
As tumoral cells are shed into the pancreatic duct and juice
in ductal adenocarcinoma, the number of malignant cells in
pancreatic juice may be higher in these cases. For this reason,
subgroup analysis of 30 Indicator genes using Spearman’s
correlation test was performed in the ductal adenocarcinoma
samples (n¼11). Expression levels between pancreatic juice and
tissue samples in ANXA1 gene were correlated with q-values
o0.05, Qp0.002; the correlation coefficients are shown in Table 2.
Gene expression levels in pancreatic juice and tissue
samples in pancreatic cancer compared with chronic
pancreatitis
Mann–Whitney U-test did not identify any genes with statistically
different expression between cancer and benign samples in
pancreatic juice samples. Of the 30 Indicator genes studied in
pancreatic tissue, only KLK3 was not expressed in pancreatic
cancer or chronic pancreatitis samples. Mann–Whitney U test
identified three genes, namely IGFBP3 (Pp0.035), PSCA
(Pp0.001) and SPINK1 (Pp0.055), with statistically different
expression between cancerous and benign pancreatic tissue
samples (Figure 2).
DISCUSSION
Use of gene expression profiles represents an innovative approach
to cancer classification and prognostication and has been applied
to an increasingly wide range of cancers. Measurement of these
gene signatures by real-time PCR would enable translation to
clinical use, whereas their analysis in pancreatic juice would allow
noninvasive diagnosis and monitoring. This study tests whether
these gene signatures can be identified in pancreatic ductal juice as
this is a relatively easily accessible biological material. For the
purposes of this study, we have compared gene signatures in ductal
juice with those in the pancreatic tumour specimen in the same
patient. As not all patients undergoing resection had adenocarci-
noma, we have also examined for differences in gene expression
profile between juice and pancreatic tissue in patients with either
benign disease or cancer.
This study demonstrated that three genes, IGFBP3, SPINK1 and
PSCA, can differentiate, in tissue samples, cancerous samples from
benign samples (normal and chronic pancreatitis cases). It also
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Figure 1 Gene expression in 30 Indicator genes after normalisation to reference genes. This graph illustrates the median gene expression values (Ct values
in log scale, after normalisation for GAPDH and PSMB6) in pancreatic juice and tissue samples. Pancreatic juice and tissue were tested for 30 Indicator genes.
The KLK3 gene was not expressed in any of the samples tested.
Table 1 Spearman’s correlation coefficients of pancreatic juice vs
pancreatic tissue
Gene
Sig.
(two-tailed)
P-value
Q-value
(FDR) Gene
Sig.
(two-tailed)
P-value
Q-value
(FDR)
CPB1 0.328 0.791 IL8 0.355 0.791
TFF2 0.940 0.971 MSLN 0.037* 0.444
EGFR 0.946 0.971 NMU 0.229 0.791
IGFBP3 0.732 0.941 NNMT 0.639 0.941
AMACR 0.770 0.941 POSTN 0.528 0.941
ARMET 0.772 0.941 SLPI 0.712 0.941
JAG1 0.874 0.971 CDH3 0.209 0.791
KRT7 0.228 0.791 GPRC5A 0.560 0.941
MMP11 0.311 0.791 LCN2 0.176 0.791
MTA1 0.779 0.941 NQO1 0.639 0.941
NME1 0.283 0.791 PLAT 0.046* 0.444
S100P 0.479 0.926 PRSS2 0.311 0.791
SPINK1 0.885 0.971 PSCA 0.971 0.971
ANXA1 0.043* 0.444 TIMP1 0.105 0.761
CEACAM6 0.475 0.926 KLK3 Not expressed Not expressed
Abbreviations: ANXA1¼annexin A1; ARMET¼now called MANF, mesencephalic
astrocyte-derived neurotrophic; AMACR¼a-methylacyl-CoA racemase; CEACAM6¼
carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting
antigen); CDH3¼cadherin 3, type 1, P-cadherin (placental); CPB1¼carboxypeptidase
B1; EGFR¼epidermal growth factor receptor;F D R ¼false discovery rate;
GPRC5A¼G protein-coupled receptor family C, group5 member A factor;
IL8¼interleukin 8; IGFBP3¼insulin-like growth factor binding protein 3; JAG1¼jagged 1;
KLK3¼kallikrein-related peptidase 3; KRT7¼keratin 7; LCN2¼lipocalin 2; MSLN¼
mesothelin; MMP11¼matrix metallopeptidase 11 (stromelysin 3); MTA1¼metastasis
associated 1; NQO1¼NAD(P)H dehydrogenase, quinone 1; NMU¼neuromedin U;
NNMT¼nicotinamide N-methyltransferase; NME1¼non-metastatic cells 1, protein
(NM23A) expressed in; POSTN¼periostin, osteoblast specific factor; PLAT¼plasminogen
activator, tissue; PRSS2¼protease, serine, 2 (trypsin 2); PSCA¼prostate stem cell antigen;
S100P¼S100 calcium binding protein P; SPINK1¼serine peptidase inhibitor, Kazal type 1;
SLPI¼secretory leukocyte peptidase inhibitor; TFF2¼trefoil factor 2; TIMP¼TIMP
metallopeptidase inhibitor 1. *Po0.05.
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genes predictive of pancreatic cancer in pancreatic juice. There was
a significant correlation between ANXA1 gene expressed in
pancreatic cancer juice and tissue samples when ductal adeno-
carcinoma samples were analysed as a discrete cohort. Annexin I
belongs to a family of Ca
2þ-dependent phospholipid-binding
proteins with phospholipase A2 inhibitory activity. Annexin I is a
steroid-regulated protein and thus implicated in some actions of
glucocorticoids, including inhibition of cell proliferation, anti-
inflammatory effects, the regulation of cell migration, differentia-
tion, death and the hypothalamic–pituitary axis. The molecular
mechanisms and the clinical significance of annexin I altered
expression in malignancies still remain a debate. Results from
several studies demonstrated that overexpression of ANXAI is a
frequent event in pancreatic cancer, which may be one of the
factors associated with malignant transformation, de-differentia-
tion and poor prognosis of pancreatic cancer (Han et al, 2002;
Iacobuzio-Donahue et al, 2002; Iacobuzio-Donahue et al, 2003a,b;
Bai et al, 2004; Grutzmann et al, 2004).
The lack of significant statistical correlation between gene
expression in pancreatic juice and tissue samples for the majority
of the Indicator genes may be because of the small amount of RNA
in pancreatic juice and to RNA degradation by RNases, which
could affect certain transcripts more than others. Additionally,
there is no clear evidence as to whether the origin of the
differentially expressed mRNAs in the pancreatic juice is from
secreted RNA or released tumour cells, and the different mRNA
levels found in the pancreatic juice compared with the solid
tumour may merely reflect a sub-population of mRNAs that are
preferentially secreted or cells that are preferentially shed that are
nevertheless indicative of pancreatic cancer (Tomlinson and Korc,
2006). In addition, the mRNAs measured in pancreatic juice may
reflect cells involved in inflammatory responses.
Three genes, IGFBP3, SPINK1 and PSCA, showed differential
expression between cancerous and benign samples. The IGFBP3 is
a gene member of the insulin-like growth factor binding protein
(IGFBP) family, and encodes a protein with an IGFBP domain and
a thyroglobulin type-I domain (Hansel et al, 2004). Insulin-like
Table 2 Spearman’s correlation coefficients of pancreatic juice vs
pancreatic tissue in ductal adenocarcinoma samples only
Gene
Sig.
(two-tailed)
P-value
Q-value
(FDR) Gene
Sig.
(two-tailed)
P-value
Q-value
(FDR)
CPB1 0.108 0.358 IL8 0.265 0.421
TFF2 0.770 0.446 MSLN 0.667 0.444
EGFR 0.019* 0.145 NMU 0.104 0.358
IGFBP3 0.667 0.444 NNMT 0.610 0.444
AMACR 0.200 0.421 POSTN 0.787 0.446
ARMET 0.787 0.446 SLPI 0.405 0.421
JAG1 0.397 0.421 CDH3 0.505 0.429
KRT7 0.787 0.446 GPRC5A 0.433 0.421
MMP11 0.289 0.421 LCN2 0.332 0.421
MTA1 0.624 0.444 NQO1 0.955 0.521
NME1 0.294 0.421 PLAT 0.420 0.421
S100P 0.987 0.521 PRSS2 0.117 0.358
SPINK1 0.326 0.421 PSCA 0.468 0.421
ANXA1 0.002* 0.03 TIMP1 0.603 0.444
CEACAM6 0.460 0.421 KLK3 Not expressed Not expressed
Abbreviations: ARMET¼now called MANF, mesencephalic astrocyte-derived
neurotrophic; AMACR¼a-methylacyl-CoA racemase; ANXA1¼annexin A1;
CPB1¼carboxypeptidase B1; CDH3¼cadherin 3, type 1, P-cadherin (placental);
CEACAM6¼carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific
cross reacting antigen); EGFR¼epidermal growth factor receptor;F D R¼false discovery
rate; GPRC5A¼G protein-coupled receptor family C, group5 member A factor;
IL8¼interleukin 8; IGFBP3¼insulin-like growth factor binding protein 3; JAG1¼jagged 1;
KLK3¼kallikrein-related peptidase 3; KRT7¼keratin 7; LCN2¼lipocalin 2;
MSLN¼mesothelin; MMP11¼matrix metallopeptidase 11 (stromelysin 3);
MTA1¼metastasis associated 1; NQO1¼NAD(P)H dehydrogenase, quinone 1;
NMU¼neuromedin U; NNMT¼nicotinamide N-methyltransferase; NME1¼non-metastatic
cells 1, protein (NM23A) expressed in; PLAT¼plasminogen activator, tissue; PRSS2¼protease,
serine, 2 (trypsin 2); PSCA¼prostate stem cell antigen; POSTN¼periostin, osteoblast specific
factor; S100P¼S100 calcium binding protein P; SPINK1¼serine peptidase inhibitor, Kazal type
1; SLPI¼secretory leukocyte peptidase inhibitor; TFF2¼trefoil factor 2; TIMP¼TIMP
metallopeptidase inhibitor 1. *Po0.05.
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Figure 2 Expression levels of SPINK1, PSCA and IGFBP3 in pancreatic
tissue with statistically significant difference between patients with either
benign or malignant disease. SPINK 1, PSCA and IGFBP3 were statistically
significantly higher in the benign group compared with cancerous group; for
each, maximum and minimum values are shown, together with 25, 50 and
75% confidence intervals and the means (dark squares).
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cell proliferation, differentiation and apoptosis elements important
in carcinogenesis. IGFBP-3 is the main binding protein of IGF-I,
and it circulates in the plasma, prolonging the half-life of IGFs and
altering their interaction with cell surface receptors (Hansel et al,
2004; Renehan et al, 2004). In agreement with previous microarray
studies, the present study has demonstrated that IGFBP3 is
overexpressed in pancreatic cancer and can differentiate cancerous
from benign tissue (Iacobuzio-Donahue et al, 2002; Logsdon et al,
2003; Iacobuzio-Donahue et al, 2003a; Grutzmann et al, 2004;
Missiaglia et al, 2004; Laurell et al, 2006).
The SPINK1 gene encodes pancreatic secretory trypsin inhibitor
(PSTI) and tumour-associated trypsin inhibitor (TATI), which is
secreted from ductal cells into pancreatic juice. PSTI is thought
to function in the prevention of trypsin-catalysed premature
activation of zymogens within the pancreas and the pancreatic
duct. The serum levels of PSTI increase in association with severe
inflammatory association, tissue damage and major surgery, all
of which suggest that PSTI has a role in the acute-phase
reaction (Graf and Bimmler, 2006; Paju and Stenman, 2006). The
SPINK1 gene is normally not expressed outside of the pancreas,
but its expression has been demonstrated to be elevated in
pancreatic cancer (Friess et al, 2001; Iacobuzio-Donahue et al,
2002; Iacobuzio-Donahue et al, 2003a; Grutzmann et al, 2004;
Fukushima et al, 2005), whereas the present study demonstrated
that SPINK1 is highly expressed in normal pancreatic tissue
compared with pancreatic cancer.
The PSCA gene encodes a glycoprotein that is anchored to
the cell membrane. Real-time PCR and immunohistochemistry
studies have demonstrated that PSCA has a limited normal tissue
distribution and is most strongly expressed in cells of the prostate
(Reiter et al, 1998). Recently, immunohistochemistry and northern
blot studies revealed that normal pancreatic tissue does not
express PSCA, with the exception of a single case of atrophic
pancreatic ducts (Reiter et al, 1998; Argani et al, 2001). This study
has demonstrated that PSCA is overexpressed in pancreatic cancer
and poorly expressed in normal pancreas and chronic pancreatitis,
and similar results have been found in microarray and real-time
studies (Argani et al, 2001; Ryu et al, 2002; Missiaglia et al, 2004;
Grubbs et al, 2006).
RNA extraction and quality is a critical step in gene expression
studies. To date, RNA extraction from pancreatic tissue and juice
processing has not been standardised, leading to unanswered
concerns of how to best store the collected specimen and maintain
reproducibility. The development of effective and reproducible
RNA isolation techniques depends on inhibition of contaminating
RNases, enrichment of messenger RNA species and elimination of
contaminating DNA (Kiba et al, 2007). In this study, to limit RNA
degradation, pancreatic juice and tissue were placed immediately
into an RNase inhibitor solution. To assure good RNA quality, four
different methods of RNA extraction were tested and the method
that generated the highest purity ratio (A260/A280 and A230/A260)
by spectrophotometric analysis was chosen as the final method;
RNA quality was assessed by RIN measurement and was good in a
majority of samples. As variability in the expression of reference
genes may lead to false results, this study considered all the
evidence published in the literature and selected two reference
genes, PSMB6 (proteasome subunit Y) and GAPDH (glyceral-
dehyde-3-phosphate dehydrogenase), with which RNA concentra-
tions were normalised in quantitative RT–PCR analyses (Rubie
et al, 2005).
In summary, this study provides important, novel confirmatory
evidence of the feasibility and utility of RNA analysis of pancreatic
juice and tissue by global cDNA amplification using poly(A) PCR
followed by real-time PCR measurement of specific genes. The
poly(A) cDNA technique is a sensitive, reproducible, robust and
nonexpensive technique for the analysis of RNA from pancreatic
tissue. However, poor quality may limit its application. RNA
integrity number should be part of an integral report in RNA
studies. Of particular relevance to clinical practice is the utility to
work with small index sample volumes and to generate results in a
short time frame. The results indicate that ANXA1 in pancreatic
ductal juice has translational potential as a marker of pancreatic
cancer. Furthermore, the differential expression patterns of
SPINK1, PSCA and IGFBP3 may be of value in the differentiation
of pancreatic cancer from chronic pancreatitis.
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